Certolizumab Pegol
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Certolizumab Pegol: From Rheumatoid Arthritis to Rheumatoid Vasculitis
One-Sentence Summary
Certolizumab pegol is a PEGylated anti-TNF-α biologic originally used to treat rheumatoid arthritis and related TNF-driven inflammatory diseases (axial spondyloarthritis, psoriatic arthritis, Crohn's disease). The TxGNN model predicts it may be effective for Rheumatoid Vasculitis, but this is currently supported by only 3 clinical trials (none designed specifically for this indication) and 8 publications — and most of the literature describes certolizumab pegol as a cause of vasculitis rather than a proven treatment for it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, Crohn's disease (per literature evidence in this pack; no local product label on file) |
| Predicted New Indication | Rheumatoid Vasculitis |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L4 |
| Finland Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for this candidate is not available in the evidence pack (flagged as a High-severity data gap, DG002). Based on the literature captured here, certolizumab pegol is a Fc-free, PEGylated anti-TNF-α Fab' fragment approved for rheumatoid arthritis (RA), axial spondyloarthritis, psoriatic arthritis, and Crohn's disease — diseases in which TNF-α is a central inflammatory driver.
Rheumatoid vasculitis is a severe extra-articular complication of RA, and TNF-α blockade is mechanistically plausible as a way to dampen the vascular inflammation involved. One case report (PMID 34786446) supports this direction, describing certolizumab pegol used to treat leg ulcers caused by rheumatoid vasculitis.
However, the remaining literature evidence points the other way: multiple independent case reports describe certolizumab pegol inducing vasculitis (leukocytoclastic vasculitis, hypocomplementemic urticarial vasculitis, medium-vessel vasculitis, rapidly progressive glomerulonephritis) as a paradoxical adverse drug reaction. This is a known class effect of anti-TNF agents. The evidence base is therefore internally contradictory — the same drug-disease pairing appears in the literature both as a potential treatment and as a trigger — and cannot currently be read as a clean repurposing signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Not Yet Recruiting | 80 | Perioperative immunosuppressant management in rheumatology patients undergoing shoulder arthroplasty; assesses flares, pain, and surgical complications — not disease-specific to rheumatoid vasculitis. |
| NCT01579006 | N/A | Completed | 184 | Multinational non-interventional study of tocilizumab (not certolizumab) in RA; may capture vasculitis-related safety data as a secondary observation. |
| NCT05696106 | N/A | Unknown | 750,000 | Large real-world study of incident immune-mediated inflammatory disease risk in patients on biologics/immunosuppressants; could capture vasculitis signals but status is unknown and not indication-specific. |
None of these trials directly evaluate certolizumab pegol as a treatment for rheumatoid vasculitis.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36418084 | 2022 | Review | RMD Open | Comparative review of infection profiles across immune-modulatory drugs, based on product-label adverse event data. |
| 36597972 | 2022 | Cohort | RMD Open | 80-patient cohort on long-term certolizumab pegol for IMID-associated uveitis (not rheumatoid vasculitis) — adjacent safety/efficacy data only. |
| 29610119 | 2018 | Case series | Clinical Medicine & Research | Single-center experience of cutaneous adverse events associated with biologic agents, including certolizumab. |
| 34786446 | 2021 | Case report | JAAD Case Reports | Certolizumab pegol used to treat leg ulcers caused by rheumatoid vasculitis. |
| 31990069 | 2020 | Case report (drug-induced) | Journal of Clinical Pharmacy and Therapeutics | Hypocomplementemic urticarial vasculitis developing during certolizumab pegol treatment for RA. |
| 28405087 | 2017 | Case report (ADR) | Proceedings (Baylor University Medical Center) | Leukocytoclastic vasculitis as a drug reaction to certolizumab pegol. |
| 41158918 | 2025 | Case report (ADR) | Cureus | Anti-TNF (certolizumab)-related medium-vessel vasculitis, reported as a rare adverse drug reaction. |
| 32687015 | 2021 | Case report (ADR) | Modern Rheumatology Case Reports | Rapidly progressive glomerulonephritis after certolizumab pegol initiation, a paradoxical autoimmune reaction. |
Six of the eight publications describe certolizumab pegol as a trigger of vasculitis rather than a treatment for it; only one supports a therapeutic use.
Finland Market Information
Certolizumab pegol is currently not marketed in Finland, and no product authorizations are on file in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information. TFDA/Fimea label warnings and contraindications could not be retrieved (data gap DG001, Blocking severity), and no drug-drug interaction data is available.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to L4 (case reports and mechanism-level reasoning) and is internally contradictory — the same drug-disease pairing appears in the literature both as a possible treatment (1 case report) and as a cause of vasculitis (6 case reports). No trial directly tests certolizumab pegol for rheumatoid vasculitis. Combined with the absence of local label safety data (DG001, Blocking), this candidate cannot advance past initial screening (S1).
To proceed, the following is needed:
- Fimea/TFDA package insert (warnings, contraindications) — currently blocking safety review (DG001)
- Formal mechanism-of-action documentation (DG002)
- A focused literature review distinguishing "certolizumab-induced vasculitis" reports from genuine treatment-use reports, to determine whether the safety signal outweighs the therapeutic signal
- If pursued further, a case-control or pharmacovigilance analysis (e.g., FAERS/VigiBase) to quantify net vasculitis risk vs. benefit before considering any prospective study
Note: Within this same evidence pack, polyarticular juvenile rheumatoid arthritis (rank 5, L2/S2) has a dedicated completed Phase 3 PK/safety/efficacy trial (NCT01550003, N=193) and represents a substantially stronger near-term candidate than rheumatoid vasculitis.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.